JOJennifer Oliva

Jennifer Oliva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer Oliva has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 in RSV Seronegative Children

    by Coleen K Cunningham, Ruth A Karron, Elizabeth J McFarland, Mark J Giganti, Rachel Ketchum, Charlotte Perlowski, Jennifer Libous, Haley Brozik, Jennifer Oliva, Dwight E Yin, et al.

    Background: A respiratory syncytial virus (RSV) vaccine, eliciting active immunity could significantly impact child health. This study evaluated 3 intranasal live-attenuated candidate RSV vaccines, RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and RSV/276 to placebo. Methods: Healthy, RSV-seronegative children aged 6–24 monthswere randomized to receive 1 of 3 candidate vaccines or placebo. Participants were monitored for vaccine reactogenicity and RSV serum antibodies. Results: Between years 2019 and 2023, 67 participants were randomized, 20 each to RSV/ΔNS2/Δ1313/I1314L, RSV/6120/ΔNS2/1030s, and placebo and 7 to RSV/276. The RSV/276 arm closed early due to an excess of mild cough in another study. The proportion (95% CI) of children experiencing at least 1 solicited adverse event during the 28 days after inoculation was 55% (32%, 77%) in RSV/ΔNS2/Δ1313/I1314L, 40% (19%, 64%) in RSV/6120/ΔNS2/1030s, 71% (29%, 96%) in RSV/276, and 55% (32%, 77%) in placebo. Events were mostly Grade 1 and often associated with other viruses. The proportion of children with ≥4-fold increase in serum RSV-neutralizing antibody titer in each vaccine arm (>70%) was significantly greater than the placebo arm (15%). Conclusions: RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s had excellent safety and immunogenicity;assessment of RSV/276 was limited by the small sample size. RSV/ΔNS2/Δ1313/I1314L and RSV/6120/ΔNS2/1030s were deemed suitable for further evaluation. Clinical Trials Registration: NCT03916185.

  • Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children

    by Ruth A Karron, Suzanne Woods, Kimberli Wanionek, Jennifer Oliva, Lijuan Yang, Cindy Luongo, Peter L Collins, Ursula J Buchholz

    The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.